Cargando…
Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program
BACKGROUND: In February 2012 the ten-valent pneumococcal conjugate vaccine (PCV10) with a 2+1 doses schedule (3, 5, 12 or 14 months of age) without catch-up vaccination was introduced in Austria. We assessed direct and indirect vaccine effects on invasive pneumococcal disease (IPD) by a population-b...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328268/ https://www.ncbi.nlm.nih.gov/pubmed/30629620 http://dx.doi.org/10.1371/journal.pone.0210081 |
_version_ | 1783386622649171968 |
---|---|
author | Richter, Lukas Schmid, Daniela Kanitz, Elisabeth Eva Zwazl, Ines Pöllabauer, Eva Jasinska, Joanna Burgmann, Heinz Kundi, Michael Wiedermann, Ursula |
author_facet | Richter, Lukas Schmid, Daniela Kanitz, Elisabeth Eva Zwazl, Ines Pöllabauer, Eva Jasinska, Joanna Burgmann, Heinz Kundi, Michael Wiedermann, Ursula |
author_sort | Richter, Lukas |
collection | PubMed |
description | BACKGROUND: In February 2012 the ten-valent pneumococcal conjugate vaccine (PCV10) with a 2+1 doses schedule (3, 5, 12 or 14 months of age) without catch-up vaccination was introduced in Austria. We assessed direct and indirect vaccine effects on invasive pneumococcal disease (IPD) by a population-based intervention study. METHODS: The study period was divided into pre- (2009–2011) and post-period (2013–2017, February), regarding 2012 as transition year. Outcomes were defined as PCV10 ST-IPD, the PCV10-related ST 6A and 19A IPD and non-PCV10 excluding ST 6A-/19A-IPD (NVT-IPD). We used national surveillance data and compared average monthly incidence rate (IR) between pre- and post-period among <5, 5–49 and ≥50 years old. Additionally, for the 5–49 and ≥50 years old, and the 50–59 and ≥60 years old, we analyzed monthly incidence data of the pre-, post-period, and estimated trend and level changes by using a segmented time-series regression. RESULTS: The PCV-10 IPD was reduced by 58% (95% CI: 30%; 74%) and 67% (95% CI: 32%; 84%) among <5 and ≥50 years old; the reduction in ≥60 years was 71% (95% CI: 36%; 88%). There were no significant changes in the pre-post-rate or incidence trend of NVT-IPD in the <5 and ≥50 years old. ST-specific analyses revealed no ST 6A- and ST 19A IPD decline in any age-group, and a ST 8 IPD increase among ≥50 years old (IR ratio: 3.5; 95% CI: 1.7; 7.2). We found no vaccine effects among 5–49 years old. CONCLUSIONS: Our study adds to the evidence on direct and indirect protection of a childhood PCV10 vaccine program. Elderlies seem to benefit the most. Findings did not support PCV 10 cross-protection, but indicate replacement at least for ST 8 among the ≥50 years old. Follow-up analyses of IPD surveillance data are needed to fully characterize the magnitude of serotype replacement and further vaccine-attributable IPD reduction with time. |
format | Online Article Text |
id | pubmed-6328268 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-63282682019-02-01 Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program Richter, Lukas Schmid, Daniela Kanitz, Elisabeth Eva Zwazl, Ines Pöllabauer, Eva Jasinska, Joanna Burgmann, Heinz Kundi, Michael Wiedermann, Ursula PLoS One Research Article BACKGROUND: In February 2012 the ten-valent pneumococcal conjugate vaccine (PCV10) with a 2+1 doses schedule (3, 5, 12 or 14 months of age) without catch-up vaccination was introduced in Austria. We assessed direct and indirect vaccine effects on invasive pneumococcal disease (IPD) by a population-based intervention study. METHODS: The study period was divided into pre- (2009–2011) and post-period (2013–2017, February), regarding 2012 as transition year. Outcomes were defined as PCV10 ST-IPD, the PCV10-related ST 6A and 19A IPD and non-PCV10 excluding ST 6A-/19A-IPD (NVT-IPD). We used national surveillance data and compared average monthly incidence rate (IR) between pre- and post-period among <5, 5–49 and ≥50 years old. Additionally, for the 5–49 and ≥50 years old, and the 50–59 and ≥60 years old, we analyzed monthly incidence data of the pre-, post-period, and estimated trend and level changes by using a segmented time-series regression. RESULTS: The PCV-10 IPD was reduced by 58% (95% CI: 30%; 74%) and 67% (95% CI: 32%; 84%) among <5 and ≥50 years old; the reduction in ≥60 years was 71% (95% CI: 36%; 88%). There were no significant changes in the pre-post-rate or incidence trend of NVT-IPD in the <5 and ≥50 years old. ST-specific analyses revealed no ST 6A- and ST 19A IPD decline in any age-group, and a ST 8 IPD increase among ≥50 years old (IR ratio: 3.5; 95% CI: 1.7; 7.2). We found no vaccine effects among 5–49 years old. CONCLUSIONS: Our study adds to the evidence on direct and indirect protection of a childhood PCV10 vaccine program. Elderlies seem to benefit the most. Findings did not support PCV 10 cross-protection, but indicate replacement at least for ST 8 among the ≥50 years old. Follow-up analyses of IPD surveillance data are needed to fully characterize the magnitude of serotype replacement and further vaccine-attributable IPD reduction with time. Public Library of Science 2019-01-10 /pmc/articles/PMC6328268/ /pubmed/30629620 http://dx.doi.org/10.1371/journal.pone.0210081 Text en © 2019 Richter et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Richter, Lukas Schmid, Daniela Kanitz, Elisabeth Eva Zwazl, Ines Pöllabauer, Eva Jasinska, Joanna Burgmann, Heinz Kundi, Michael Wiedermann, Ursula Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program |
title | Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program |
title_full | Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program |
title_fullStr | Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program |
title_full_unstemmed | Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program |
title_short | Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program |
title_sort | invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the austrian national immunization program |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328268/ https://www.ncbi.nlm.nih.gov/pubmed/30629620 http://dx.doi.org/10.1371/journal.pone.0210081 |
work_keys_str_mv | AT richterlukas invasivepneumococcaldiseasesinchildrenandadultsbeforeandafterintroductionofthe10valentpneumococcalconjugatevaccineintotheaustriannationalimmunizationprogram AT schmiddaniela invasivepneumococcaldiseasesinchildrenandadultsbeforeandafterintroductionofthe10valentpneumococcalconjugatevaccineintotheaustriannationalimmunizationprogram AT kanitzelisabetheva invasivepneumococcaldiseasesinchildrenandadultsbeforeandafterintroductionofthe10valentpneumococcalconjugatevaccineintotheaustriannationalimmunizationprogram AT zwazlines invasivepneumococcaldiseasesinchildrenandadultsbeforeandafterintroductionofthe10valentpneumococcalconjugatevaccineintotheaustriannationalimmunizationprogram AT pollabauereva invasivepneumococcaldiseasesinchildrenandadultsbeforeandafterintroductionofthe10valentpneumococcalconjugatevaccineintotheaustriannationalimmunizationprogram AT jasinskajoanna invasivepneumococcaldiseasesinchildrenandadultsbeforeandafterintroductionofthe10valentpneumococcalconjugatevaccineintotheaustriannationalimmunizationprogram AT burgmannheinz invasivepneumococcaldiseasesinchildrenandadultsbeforeandafterintroductionofthe10valentpneumococcalconjugatevaccineintotheaustriannationalimmunizationprogram AT kundimichael invasivepneumococcaldiseasesinchildrenandadultsbeforeandafterintroductionofthe10valentpneumococcalconjugatevaccineintotheaustriannationalimmunizationprogram AT wiedermannursula invasivepneumococcaldiseasesinchildrenandadultsbeforeandafterintroductionofthe10valentpneumococcalconjugatevaccineintotheaustriannationalimmunizationprogram |